Wang Yong-Ping
The Fifth People's Hospital of Suzhou 215007, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009 Aug;23(4):304-6.
Investigation in the role of neutralizing anti-interferon antibodies(NA) during interferon therapy in patients with chronic hepatitis B.
To measure the levels of NA in 48 patients with chronic hepatitis B (CHB) treated with interferon-alpha (IFN-alpha) at the point before treated and at 3 and 6 months with treatment respectively. At the same time to measure the levels of NA in health volunteers.
NA can not be measured in health volunteers and those patients with CHB at the point before treated. At the point of 6 months with treatment, 15 patients with CHB got complete respond, 10 patients with CHB got no respond, 23 patients with CHB got partly respond, respectively. NA positive rate was 25% at 3 months and 37.5% at 6 months with treatment, respectively. (P > 0.05). NA positive rate was significantly higher in complete responders group and partly responders group than in no responders group at 3 months with. NA positive rate was significantly higher in complete responders group than in no responders group at 3 months with.
NA can be measured in blood serum after treated with interferon. NA influences the efficacy of interferon, especially at 3 months.
研究中和性抗干扰素抗体（NA）在慢性乙型肝炎患者干扰素治疗中的作用。
检测48例接受α干扰素（IFN-α）治疗的慢性乙型肝炎（CHB）患者治疗前、治疗3个月和6个月时的NA水平。同时检测健康志愿者的NA水平。
健康志愿者和CHB患者治疗前均未检测到NA。治疗6个月时，CHB患者中15例完全应答，10例无应答，23例部分应答。治疗3个月和6个月时NA阳性率分别为25%和37.5%。（P>0.05）。治疗3个月时，完全应答组和部分应答组的NA阳性率显著高于无应答组。治疗3个月时，完全应答组的NA阳性率显著高于无应答组。
干扰素治疗后血清中可检测到NA。NA影响干扰素疗效，尤其是在3个月时。
